Assessment of Filamin-A Levels in Patients with Acromegaly Only and those Associated with Diabetes Mellitus

Background: Acromegaly is a rare endocrine disorder characterized by elevated levels of insulin-like growth factor-1 and growth hormone, which are typically brought on by a somatotroph adenoma of the pituitary gland. It has an incidence of 4 per million annually and a prevalence of 40 per million. The elevated IGF-1 levels cause somatic growth and metabolic effects, with subsequently increased morbidity and mortality, particularly when GH and IGF-1 levels remain persistently elevated. Objective: To evaluate the levels of filamin-A (FLNA) in patients with acromegaly with and without diabetes mellitus type 2 (T2DM) compared to a control group. Methods: In this case-control study, one hundred patients with acromegaly registered at the National Diabetes Center, Mustansiriyah University, were enrolled in the study. 76 participants as control. All recruited participants have given oral consent to participate in the study, which was conducted from February 2024 to August 2024. Results: The age distribution differences were not statistically significant. The gender distribution showed 47 females and 53 males in the acromegaly group. The FLNA level was higher among patients compared to controls and showed the highest level in acromegaly and DM (687.24 ng/L), followed by acromegaly without DM (359.39 ng/L), controls with DM (205.96 ng/L), and controls without DM (143.29 ng/L). Conclusions: The results showed that serum FLNA was elevated in patients with acromegaly in comparison to the control group and in the T2DM group versus those without T2DM.